

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 27, 2006

DELCATH SYSTEMS, INC.
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	001-16133 (Commission File Number)	06-1245881 (IRS Employer Identification No.)
---	---------------------------------------	--

1100 Summer Street, Stamford, Connecticut (Address of principal executive offices)	06905 (Zip Code)
---	---------------------

Registrant's telephone number, including area code: (203) 323-8668

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 8 - Other Events

Item 8.01 Other Events.

On September 27, 2006, Delcath Systems, Inc. (the "Company") issued a press release announcing two developments in the Company's federal securities lawsuit against Laddcap Value Partners LP. The Company's press release dated September 27, 2006 is incorporated herein by reference and filed as Exhibit 99 hereto.

Section 9 - Financial Statements and Exhibits.

Item 9.01. Financial Statements and Exhibits.

- (a) Not applicable.
- (b) Not applicable.
- (c) Not applicable.
- (d) Exhibits:

Exhibit

Description

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DELCATH SYSTEMS, INC.

By: /s/ M. S. KOLY

M. S. Koly
President and Chief Executive
Officer

Date: September 29, 2006

EXHIBIT INDEX

Exhibit

Description

99

Press Release dated September 27, 2006 of Delcath
Systems, Inc.

[GRAPHIC OMITTED]

Company Contact:
Delcath Systems, Inc.
M. S. Koly, Chief Executive Officer
203-323-8668
www.delcath.com
- - - - -

Investor Contacts:
Todd Fromer / Garth Russell
KCSA Worldwide
(212) 896-1215 / (212) 896-1250
tfromer@kcsa.com / grussell@kcsa.com
- - - - -

Media Contacts:
Lewis Goldberg
KCSA Worldwide
(212) 896-1216
lgoldberg@kcsa.com
- - - - -

FOR IMMEDIATE RELEASE

Laddcap Counterclaim Against Delcath Dismissed And Temporary
Restraining Order Against Laddcap Modified In Federal Securities Lawsuit
- - -

STAMFORD, Conn., September 27, 2006 -- Delcath Systems, Inc. (NASDAQ: DCTH) today announced two developments in the Company's federal securities lawsuit against Laddcap Value Partners LP. First, a counterclaim recently asserted by Laddcap against Delcath has been dismissed by Laddcap without prejudice.

In addition, the temporary restraining order in the action has been modified to allow Laddcap to file the consents it has obtained from its Consent Solicitation. However, the United States Court of Appeals for the Second Circuit has ordered that "all further action to give effect to those consents (including the counting of the consents and disclosure of their contents) continues to be stayed" pending further adjudication of Delcath's claims against Laddcap.

The lawsuit is now back before the Honorable Loretta A. Preska of the U.S. District Court for the Southern District of New York for further proceedings on Delcath's claims. As previously announced, the district court has found that Delcath has "a likelihood of success on the merits of its [Section] 13(d) and 14(a) claims" against Laddcap.

About Delcath Systems, Inc.

Delcath Systems is a developer of isolated perfusion technology for organ or region-specific delivery of therapeutic agents. The Company's intellectual property portfolio currently consists of 12 patents on a worldwide basis, including the United States, Europe, Asia and Canada. For more information, please visit the Company's website, www.delcath.com.

This release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other

resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

#